Abdallah Mohammad, Badawi Mohammad, Alzaagi Ibrahim, Issa Khaddash Nedal, Rasheed Akram, Alharthy Abdurahman
Pharmaceutical Care Services, King Saud Medical City , Riyadh , Saudi Arabia.
Prevention and Control of Infection Administration, King Saud Medical City , Riyadh , Saudi Arabia.
J Chemother. 2019 Sep;31(5):261-266. doi: 10.1080/1120009X.2019.1601802. Epub 2019 Apr 14.
We conducted a two-phase retrospective study to investigate the impact of a short-term carbapenem restriction on the incidence of non-pseudomonal multidrug-resistant (MDR) Gram-negative bacilli in our intensive care unit (ICU). The first phase of the study (before carbapenem restriction) was conducted between May and July 2016, and the second phase (implementation of carbapenem restriction) between September and November 2016. The incidence of all non-pseudomonal MDR Gram-negative bacilli (extended-spectrum β-lactamase-producing , carbapenem-resistant and MDR ) decreased significantly after carbapenem restriction. Patients positive for non-pseudomonal MDR Gram-negative bacilli before and after carbapenem restriction were comparable in terms of age, weight, Acute Physiology and Chronic Health Evaluation IV score, central venous catheter placement, and vasopressor use. This report suggests that short-term carbapenem restriction for 3 months may be an effective strategy for reducing the incidence of non-pseudomonal MDR Gram-negative bacilli.
我们进行了一项两阶段回顾性研究,以调查短期碳青霉烯类药物限制对我们重症监护病房(ICU)中非假单胞菌多重耐药(MDR)革兰氏阴性杆菌发生率的影响。研究的第一阶段(碳青霉烯类药物限制前)于2016年5月至7月进行,第二阶段(碳青霉烯类药物限制实施)于2016年9月至11月进行。碳青霉烯类药物限制后,所有非假单胞菌MDR革兰氏阴性杆菌(产超广谱β-内酰胺酶、耐碳青霉烯类和MDR)的发生率显著下降。碳青霉烯类药物限制前后非假单胞菌MDR革兰氏阴性杆菌阳性的患者在年龄、体重、急性生理与慢性健康状况评分系统IV评分、中心静脉导管置入和血管加压药使用方面具有可比性。本报告表明,为期3个月的短期碳青霉烯类药物限制可能是降低非假单胞菌MDR革兰氏阴性杆菌发生率的有效策略。